Tumor lysis with LTX-401 creates anticancer immunity

Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401,...

詳細記述

保存先:
書誌詳細
出版年:Oncoimmunology
主要な著者: Xie, Wei, Mondragón, Laura, Mauseth, Brynjar, Wang, Yan, Pol, Jonathan, Lévesque, Sarah, Zhou, Heng, Yamazaki, Takahiro, Eksteen, Johannes J., Zitvogel, Laurence, Sveinbjørnsson, Baldur, Rekdal, Øystein, Kepp, Oliver, Kroemer, Guido
フォーマット: Artigo
言語:Inglês
出版事項: Taylor & Francis 2019
主題:
Brief Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6527292/
https://ncbi.nlm.nih.gov/pubmed/31143516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1594555
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料